Louise Rodino-Klapac - Mar 1, 2024 Form 4 Insider Report for Sarepta Therapeutics, Inc. (SRPT)

Role
Head of R&D, CSO
Signature
/s/ Ryan Brown, as Attorney-in-Fact for Louise Rodino-Klapac
Stock symbol
SRPT
Transactions as of
Mar 1, 2024
Transactions value $
-$98,176
Form type
4
Date filed
3/5/2024, 08:00 PM
Previous filing
Nov 20, 2023
Next filing
Mar 6, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SRPT Common Stock Tax liability -$98.2K -778 -1.18% $126.19 65.2K Mar 1, 2024 Direct F1, F2
transaction SRPT Common Stock Award $0 +6K +9.2% $0.00 71.2K Mar 1, 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SRPT Stock Option (right to buy) Award $0 +12.5K $0.00 12.5K Mar 1, 2024 Common Stock 12.5K $128.67 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on February 28, 2020.
F2 Amount of Securities Beneficially Owned includes 249 shares purchased under the Company's registered Employee Stock Purchase Plan on February 29, 2024.
F3 The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest on the first anniversary of the grant date, and additional 25% will vest on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested on the fourth anniversary of the grant date.
F4 Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter.